Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 2.96
- Piotroski Score 7.00
- Grade Buy
- Symbol (SNY)
- Company Sanofi
- Price $51.74
- Changes Percentage (0.94%)
- Change $0.48
- Day Low $51.37
- Day High $51.78
- Year High $58.97
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
- Last Earnings N/A
- Ex-Dividend for 5/16 Dividend 05/09/2024
- Dividend Payable 06/06/2024
- Today N/A
- Next Earnings (Estimated) 01/30/2025
- Fiscal Year End N/A
- Average Stock Price Target $60.00
- High Stock Price Target $64.00
- Low Stock Price Target $48.07
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $1.97
- Trailing P/E Ratio 24.86
- Forward P/E Ratio 24.86
- P/E Growth 24.86
- Net Income $5.40 B
Income Statement
Quarterly
Annual
Latest News of SNY
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Love Is Blind's Stacy Snyder Recalls 'Living a Double Life' While Hiding Relationship with a Woman in Her Early 20s
Reality star Danielle Ruhl, from Love Is Blind season 5, shared her experience publicly coming out as queer on a podcast. She revealed her past relationship with a woman and the challenges of sharing ...
By PEOPLE.com | 1 week ago -
Sanofi (SNY) Q3 2024 Earnings Call Transcript
Sanofi reported strong growth in Q3 2024 with a 16% increase in CER for total sales of 13.4 billion euros. Dupixent and Vaccine business showed robust growth. Opella deal was discussed, with cash proc...
By Yahoo! Finance | 1 week ago -
Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent
Eli Lilly's Phase 3b ADapt study on Ebglyss for atopic dermatitis showed significant improvements in skin and itch, especially for patients previously treated with Dupixent. Results include a high per...
By Yahoo! Finance | 1 week ago
